Impetigo Treatment Market, By Route of Administration (Topical and Oral), By Patient Type, By Drug Class, By Distribution Channel, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
|
Report ID
AV4559
|
Published Date
December 2025
|
Pages
365
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Impetigo Treatment Market size was valued at US$ 778 Million in 2024, expanding at a CAGR of 5.8% from 2025 to 2032.
The Impetigo Treatment Market encompasses pharmaceuticals, topical antibiotics, antiseptics, and advanced dermatology solutions designed to manage impetigo, a highly contagious bacterial skin infection that primarily affects children. The market is being driven by the increasing prevalence of skin infections, often linked to poor hygiene, overcrowded living conditions, and rising bacterial resistance.
A notable trend in the market is the growing adoption of non-antibiotic and antiseptic-based therapies, reflecting global efforts to combat antimicrobial resistance. However, the market faces significant challenges due to the rise of MRSA (methicillin-resistant Staphylococcus aureus) infections, which reduce the effectiveness of conventional antibiotics and complicate treatment strategies. Despite these challenges, substantial growth opportunities exist through innovation in combination therapies, novel topical formulations, and faster-acting antimicrobial agents, offering more targeted and resistance-free treatment options. These factors collectively position the impetigo treatment market for steady growth, as healthcare systems increasingly prioritize effective skin infection management and responsible antimicrobial use.
Impetigo Treatment Market- Market Dynamics
Increasing Emphasis on Advanced Dermatology and Infectious Disease Management
The growing prevalence of skin infections and rising antibiotic resistance are key drivers of the Impetigo Treatment Market. To improve treatment outcomes, healthcare systems are increasingly prioritizing faster diagnostics, enhanced formulations, and advanced antimicrobial therapies. This trend is further supported by strategic industry initiatives that expand research capabilities. For instance, in January 2020, Novartis acquired The Medicines Company, strengthening its therapeutic pipeline and highlighting the industry’s commitment to developing innovative infectious disease solutions. While the acquisition primarily focused on inclisiran, it underscores a broader push toward high-innovation portfolios, indirectly accelerating advancements in dermatology and skin-infection therapeutics, including impetigo.
Impetigo Treatment Market- Segmentation Analysis:
The Global Impetigo Treatment Market is segmented by Route of Administration, Patient Type, Drug Class, Distribution Channel and Region.
According to the route of administration, the oral segment is important in the impetigo treatment market because it works well for moderate to severe infections, recurrent cases, and situations where topical antibiotics fail to effectively control the disease. Oral formulations such as amoxicillinclavulanate, clindamycin, and macrolides have systemic action that aids in eliminating deeper or widespread infections, making them a key choice for clinicians when localized therapy is insufficient, particularly in regions with high resistance to topical therapies. Growing antimicrobial innovation and combination therapies further contribute to this segment’s demand, as pharmaceutical companies and strategic corporate alliances strengthen research capabilities for more potent oral formulations. For example, in March 2020, Menlo Therapeutics’ merger with Foamix Pharmaceuticals bolstered its dermatology portfolio, indirectly supporting enhanced antibiotic and antiinfective therapy development for skin diseases such as impetigo. Government health data also reflects the broader context of rising skin infection burdens: agencies such as GOV.UK reported nearly 14,000 cases of Staphylococcus aureus bacteremia in the 20222023 financial year, a sign of increasing bacterial infections that can include impetigo and fuel demand for effective systemic treatments.
By distribution channel, the hospital pharmacy segment remains critical because hospitals handle more severe, rapidly spreading, or immunocompromised impetigo cases that require prompt access to validated medications and specialist care. This segment benefits from structured antibiotic stewardship programs, specialist consultations, and advanced diagnostics that help optimize treatment outcomes and limit inappropriate antibiotic use. Hospitals account for a substantial share of impetigo treatment distribution, reflecting their role as primary points of care for complex cases where both oral and topical therapies may be administered under medical supervision. The increase in hospitalbased dermatology services and outbreak management protocols further drives this segment’s importance, ensuring patients have access to dermatologistrecommended formulations during acute episodes. For instance, in November 2021, NovaBay Pharmaceuticals’ acquisition of DERMAdoctor expanded the company’s dermatologyfocused product distribution through professional channels, including hospitals, thereby improving the availability of reliable impetigo treatment options at hospital pharmacies and reinforcing care pathways within clinical settings.
Impetigo Treatment Market- Geographical Insights
North America leads the Impetigo Treatment Market due to the high prevalence of bacterial skin infections and strong public awareness of impetigo, particularly among children. The region benefits from an advanced healthcare infrastructure, widespread access to dermatologists, and well-established reimbursement systems. Government-supported public health initiatives, including programs aimed at reducing skin infections, along with the broad availability of both branded and generic medications, have accelerated market adoption. Globally, health authorities report that skin infections affect millions of children each year, highlighting the need for effective treatment solutions. High healthcare spending, routine clinical screenings, and rapid diagnostic capabilities facilitate early detection and effective treatment of impetigo cases. Furthermore, the active investment of major pharmaceutical companies in dermatology research and development, particularly in combating antibiotic resistance, reinforces North Ame
United States Impetigo Treatment Market- Country Insights
The United States is a leading market for impetigo treatment, supported by a robust healthcare infrastructure, high public awareness, and widespread access to dermatology services. The country experiences a steady incidence of bacterial skin infections, particularly among children, driving consistent demand for topical and oral antibiotics. Early diagnosis is emphasized through routine pediatric screenings, enabling timely and effective treatment. Furthermore, strong pharmaceutical innovation, supported by advanced R&D capabilities and streamlined regulatory pathways, continues to shape the market. For example, in June 2025, Sanofi received FDA approval for Dupixent (dupilumab) to treat bullous pemphigoid, an inflammatory skin disorder. While not a direct treatment for impetigo, this milestone underscores the U.S.’s growing dermatology innovation landscape, opening avenues for better management of skin infections and improving long-term patient outcomes.
Impetigo Treatment Market- Competitive Landscape:
The impetigo treatment market is highly competitive, with several key players engaged in the development, manufacturing, and commercialization of antibiotics and related therapies. Companies are increasingly focusing on strategic initiatives such as mergers and acquisitions, partnerships, and collaborations to strengthen their market positions and expand product portfolios. Innovation remains a priority, particularly in the development of new antibiotic formulations and combination therapies to combat antibiotic resistance and improve treatment outcomes. For instance, in January 2022, Pfizer received FDA approval for CIBINQO (abrocitinib), an oral inhibitor for moderate to severe dermatitis. CIBINQO offers an important oral treatment option, demonstrating efficacy in clearing skin, reducing itching, and managing eczema severity, with a favorable benefit-risk profile in the approved patient population.
Recent Developments
- NovaBay Pharmaceuticals (May 2024): Launched a telehealth dermatology service to diagnose and treat impetigo remotely. This service improves access in rural and underserved areas, reflecting a broader trend toward hybrid dermatology models and enabling patients to receive prescribed topical antibiotics conveniently.
- Ferrer (June 2025): Successfully completed Phase III trials for Ozenoxacin 1% cream to treat impetigo in pediatric and adult patients. The trials demonstrated improved clinical and bacteriological responses compared to placebo, with early improvement observed by days 3–4. The cream was well tolerated across multiple sites in the United States, Germany, South Africa, and Ukraine, positioning Ozenoxacin for a strong near-term presence in the global market.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as following:
GLOBAL IMPETIGO TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- GlaxoSmithKline plc
- Ranbaxy Laboratories Limited
- Roche Holding AG
- Karalex Pharma, LLC
- Teva Pharmaceutical Industries Ltd
- Pfizer, Inc
- SANDOZ GmbH
- NovaBay Pharmaceuticals, Inc.
- Lupin Limited
- Leo Pharma A/S
- Taro Pharmaceutical Industries Ltd
- Others
GLOBAL IMPETIGO TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032
- Topical
- Oral
GLOBAL IMPETIGO TREATMENT MARKET, BY PATIENT TYPE- MARKET ANALYSIS, 2019 - 2032
- Children
- Elderly
- Adults
GLOBAL IMPETIGO TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032
- Cephalosporins
- Quinolones
- Sulfonamides
- Fusidane
- Lincosamide
- Penicillin
- Tetracycline
- Others
GLOBAL IMPETIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
GLOBAL IMPETIGO TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Impetigo Treatment Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Impetigo Treatment Market Snippet by Route of Administration
2.1.2. Impetigo Treatment Market Snippet by Patient Type
2.1.3. Impetigo Treatment Market Snippet by Drug Class
2.1.4. Impetigo Treatment Market Snippet by Distribution Channel
2.1.5. Impetigo Treatment Market Snippet by Country
2.1.6. Impetigo Treatment Market Snippet by Region
2.2. Competitive Insights
3. Impetigo Treatment Key Market Trends
3.1. Impetigo Treatment Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Impetigo Treatment Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Impetigo Treatment Market Opportunities
3.4. Impetigo Treatment Market Future Trends
4. Impetigo Treatment Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Impetigo Treatment Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Impetigo Treatment Market Landscape
6.1. Impetigo Treatment Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Impetigo Treatment Market – By Route of Administration
7.1. Overview
7.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
7.1.2. Topical
7.1.3. Oral
8. Impetigo Treatment Market – By Patient Type
8.1. Overview
8.1.1. Segment Share Analysis, By Patient Type, 2024 & 2032 (%)
8.1.2. Children
8.1.3. Elderly
8.1.4. Adults
9. Impetigo Treatment Market – By Drug Class
9.1. Overview
9.1.1. Segment Share Analysis, By Drug Class, 2024 & 2032 (%)
9.1.2. Cephalosporins
9.1.3. Quinolones
9.1.4. Sulfonamides
9.1.5. Fusidane
9.1.6. Lincosamide
9.1.7. Penicillin
9.1.8. Tetracycline
9.1.9. Others
10. Impetigo Treatment Market – By Distribution Channel
10.1. Overview
10.1.1. Segment Share Analysis, By Patient Type, 2024 & 2032 (%)
10.1.2. Hospital Pharmacies
10.1.3. Retail Pharmacies
10.1.4. Online Pharmacies
11. Impetigo Treatment Market– By Geography
11.1. Introduction
11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
11.2. North America
11.2.1. Overview
11.2.2. Impetigo Treatment Key Manufacturers in North America
11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.2.4. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.2.5. North America Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
11.2.6. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.2.7. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.2.8. U.S.
11.2.8.1. Overview
11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.2.8.3. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.2.8.4. U.S. Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
11.2.8.5. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.2.8.6. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.2.9. Canada
11.2.9.1. Overview
11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.2.9.3. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.2.9.4. Canada Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
11.2.9.5. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.2.9.6. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3. Europe
11.3.1. Overview
11.3.2. Impetigo Treatment Key Manufacturers in Europe
11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.3.4. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.5. Europe Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
11.3.6. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.7. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.8. Germany
11.3.8.1. Overview
11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.8.3. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.8.4. Germany Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
11.3.8.5. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.8.6. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.9. UK
11.3.9.1. Overview
11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.9.3. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.9.4. UK Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
11.3.9.5. UK Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.9.6. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.10. France
11.3.10.1. Overview
11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.10.3. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.10.4. France Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
11.3.10.5. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.10.6. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.11. Italy
11.3.11.1. Overview
11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.11.3. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.11.4. Italy Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
11.3.11.5. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.11.6. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.12. Spain
11.3.12.1. Overview
11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.12.3. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.12.4. Spain Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
11.3.12.5. Spain Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.12.6. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.13. The Netherlands
11.3.13.1. Overview
11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.13.3. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.13.4. The Netherlands Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
11.3.13.5. The Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.13.6. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.14. Sweden
11.3.14.1. Overview
11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.14.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.14.4. Sweden Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
11.3.14.5. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.14.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.15. Russia
11.3.15.1. Overview
11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.15.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.15.4. Russia Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
11.3.15.5. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.15.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.16. Poland
11.3.16.1. Overview
11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.16.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.16.4. Poland Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
11.3.16.5. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.17. Rest of Europe
11.3.17.1. Overview
11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.17.3. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.17.4. Rest of the Europe Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
11.3.17.5. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.17.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
11.4.1. Overview
11.4.2. Impetigo Treatment Key Manufacturers in Asia Pacific
11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.4.4. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.5. APAC Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
11.4.6. APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.7. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.8. China
11.4.8.1. Overview
11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.8.3. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.8.4. China Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
11.4.8.5. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.8.6. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.9. India
11.4.9.1. Overview
11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.9.3. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.9.4. India Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
11.4.9.5. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.9.6. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.10. Japan
11.4.10.1. Overview
11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.10.3. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.10.4. Japan Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
11.4.10.5. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.10.6. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.11. South Korea
11.4.11.1. Overview
11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.11.3. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.11.4. South Korea Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
11.4.11.5. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.11.6. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.12. Australia
11.4.12.1. Overview
11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.12.3. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.12.4. Australia Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
11.4.12.5. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.12.6. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.13. Indonesia
11.4.13.1. Overview
11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.13.3. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.13.4. Indonesia Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
11.4.13.5. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.13.6. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.14. Thailand
11.4.14.1. Overview
11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.14.3. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.14.4. Thailand Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
11.4.14.5. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.14.6. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.15. Philippines
11.4.15.1. Overview
11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.15.3. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.15.4. Philippines Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
11.4.15.5. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.15.6. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.16. Rest of APAC
11.4.16.1. Overview
11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.16.3. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.16.4. Rest of APAC Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
11.4.16.5. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.16.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.5. Latin America (LATAM)
11.5.1. Overview
11.5.2. Impetigo Treatment Key Manufacturers in Latin America
11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.5.4. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.5.5. LATAM Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
11.5.6. LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.5.7. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.5.8. Brazil
11.5.8.1. Overview
11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.8.3. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.5.8.4. Brazil Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
11.5.8.5. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.5.8.6. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.5.9. Mexico
11.5.9.1. Overview
11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.9.3. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.5.9.4. Mexico Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
11.5.9.5. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.5.9.6. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.5.10. Argentina
11.5.10.1. Overview
11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.10.3. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.5.10.4. Argentina Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
11.5.10.5. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.5.10.6. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.5.11. Colombia
11.5.11.1. Overview
11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.11.3. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.5.11.4. Colombia Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
11.5.11.5. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.5.11.6. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.5.12. Rest of LATAM
11.5.12.1. Overview
11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.12.3. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.5.12.4. Rest of LATAM Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
11.5.12.5. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.5.12.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa (MEA)
11.6.1. Overview
11.6.2. Impetigo Treatment Key Manufacturers in Middle East and Africa
11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.6.4. MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.6.5. MEA Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
11.6.6. MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.7. MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6.8. Saudi Arabia
11.6.8.1. Overview
11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.8.3. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.6.8.4. Saudi Arabia Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
11.6.8.5. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.8.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6.9. United Arab Emirates
11.6.9.1. Overview
11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.9.3. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.6.9.4. United Arab Emirates Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
11.6.9.5. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.9.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6.10. Israel
11.6.10.1. Overview
11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.10.3. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.6.10.4. Israel Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
11.6.10.5. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.10.6. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6.11. Turkey
11.6.11.1. Overview
11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.11.3. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.6.11.4. Turkey Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
11.6.11.5. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.11.6. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6.12. Algeria
11.6.12.1. Overview
11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.12.3. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.6.12.4. Algeria Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
11.6.12.5. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.12.6. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6.13. Egypt
11.6.13.1. Overview
11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.13.3. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.6.13.4. Egypt Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
11.6.13.5. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.13.6. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6.14. Rest of MEA
11.6.14.1. Overview
11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.14.3. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.6.14.4. Rest of MEA Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
11.6.14.5. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.14.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12. Key Vendor Analysis- Impetigo Treatment Industry
12.1. Competitive Benchmarking
12.1.1. Competitive Dashboard
12.1.2. Competitive Positioning
12.2. Company Profiles
12.2.1. GlaxoSmithKline plc
12.2.2. Ranbaxy Laboratories Limited
12.2.3. Roche Holding AG
12.2.4. Karalex Pharma, LLC
12.2.5. Teva Pharmaceutical Industries Ltd
12.2.6. Pfizer, Inc
12.2.7. SANDOZ GmbH
12.2.8. NovaBay Pharmaceuticals, Inc.
12.2.9. Lupin Limited
12.2.10. Leo Pharma A/S
12.2.11. Taro Pharmaceutical Industries Ltd
12.2.12. Others
13. 360 Degree AnalystView
14. Appendix
14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as following:
GLOBAL IMPETIGO TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- GlaxoSmithKline plc
- Ranbaxy Laboratories Limited
- Roche Holding AG
- Karalex Pharma, LLC
- Teva Pharmaceutical Industries Ltd
- Pfizer, Inc
- SANDOZ GmbH
- NovaBay Pharmaceuticals, Inc.
- Lupin Limited
- Leo Pharma A/S
- Taro Pharmaceutical Industries Ltd
- Others
GLOBAL IMPETIGO TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032
- Topical
- Oral
GLOBAL IMPETIGO TREATMENT MARKET, BY PATIENT TYPE- MARKET ANALYSIS, 2019 - 2032
- Children
- Elderly
- Adults
GLOBAL IMPETIGO TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032
- Cephalosporins
- Quinolones
- Sulfonamides
- Fusidane
- Lincosamide
- Penicillin
- Tetracycline
- Others
GLOBAL IMPETIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
GLOBAL IMPETIGO TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
